Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Gains from Investment Securities (2019 - 2025)

IDEAYA Biosciences' Gains from Investment Securities history spans 7 years, with the latest figure at $5.6 million for Q2 2025.

  • For Q2 2025, Gains from Investment Securities fell 55.31% year-over-year to $5.6 million; the TTM value through Dec 2025 reached $6.2 million, down 65.59%, while the annual FY2025 figure was $6.2 million, 20.05% down from the prior year.
  • Gains from Investment Securities for Q2 2025 was $5.6 million at IDEAYA Biosciences, up from $600000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $14.5 million in Q1 2024 and bottomed at -$9.5 million in Q3 2024.
  • The 5-year median for Gains from Investment Securities is $600000.0 (2022), against an average of $1.7 million.
  • The largest YoY upside for Gains from Investment Securities was 29900.0% in 2021 against a maximum downside of 9766.67% in 2021.
  • A 5-year view of Gains from Investment Securities shows it stood at -$296000.0 in 2021, then surged by 302.7% to $600000.0 in 2022, then skyrocketed by 115.67% to $1.3 million in 2023, then tumbled by 64.37% to $461000.0 in 2024, then soared by 1111.71% to $5.6 million in 2025.
  • Per Business Quant, the three most recent readings for IDYA's Gains from Investment Securities are $5.6 million (Q2 2025), $600000.0 (Q1 2025), and $461000.0 (Q4 2024).